Cardiovascular R&D Centre-UnIC@RISE, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, 4200-319, Porto, Portugal.
Relaxera GmbH & Co. KG, Bensheim, Germany.
Clin Res Cardiol. 2024 Aug;113(8):1137-1150. doi: 10.1007/s00392-023-02305-1. Epub 2023 Sep 18.
The hormone relaxin-2 has emerged as a promising player in regulating the physiology of the cardiovascular system. Through binding to the relaxin family peptide receptor 1 (RXFP1), this hormone elicits multiple physiological responses including vasodilation induction, reduction of inflammation and oxidative stress, and angiogenesis stimulation. The role of relaxin-2, or its recombinant human form known as serelaxin, has been investigated in preclinical and clinical studies as a potential therapy for cardiovascular diseases, especially heart failure, whose current therapy is still unoptimized. However, evidence from past clinical trials has been inconsistent and further research is needed to fully understand the potential applications of relaxin-2. This review provides an overview of serelaxin use in clinical trials and discusses future directions in the development of relaxin-2 mimetics, which may offer new therapeutic options for patients with heart failure.
松弛素-2 作为一种有前途的调节心血管系统生理学的因子而备受关注。通过与松弛素家族肽受体 1（RXFP1）结合，这种激素引发多种生理反应，包括血管舒张诱导、减少炎症和氧化应激以及血管生成刺激。松弛素-2 或其重组人形式称为 Serelaxin 的作用已在临床前和临床研究中作为心血管疾病，特别是心力衰竭的潜在治疗方法进行了研究，而心力衰竭的当前治疗方法仍不理想。然而，过去临床试验的证据并不一致，需要进一步的研究来充分了解松弛素-2 的潜在应用。本综述提供了松弛素-2 在临床试验中的应用概述，并讨论了松弛素-2 类似物开发的未来方向，这可能为心力衰竭患者提供新的治疗选择。
